Hard-to-detect prostate cancer may grow through cancer-stroma KRAS signaling
Researchers at Kanazawa University have identified a molecular mechanism that allows 'double-negative' prostate cancer to grow and metastasize despite androgen-deprivation therapy. By uncovering how cancer cells and surrounding stromal cells communicate via CCL2 and FGF signaling to activate the KRAS pathway, the team has identified a potential new target for drug intervention.
Why it matters
Double-negative prostate cancer is notoriously difficult to detect and treat because it does not produce standard tumor markers; this discovery of a specific signaling pathway provides a critical target for new, life-saving therapies.
edited by Sadie Harley , reviewed by Andrew Zinin
The article is a straightforward report on peer-reviewed medical research, focusing on scientific findings without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in